Sabby Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-93,308
Closed -$1.97M 226
2017
Q1
$1.97M Buy
93,308
+64,690
+226% +$1.59M 0.11% 93
2016
Q4
$806K Buy
+28,618
New +$801K 0.05% 159
2015
Q3
Sell
-30,000
Closed -$867K 387
2015
Q2
$867K Buy
+30,000
New +$758K 0.03% 226

Other funds holding CHRS

Sabby Management's CHRS Position: Q2 2017 in Review

Sabby Management sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 93,308 shares — an estimated $1.97M sold.

Sabby Management first reported a position in CHRS in Q2 2015 and held it in 3 quarters. The position peaked at $1.97M in Q1 2017. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

  • Sabby Management reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 93,308 Coherus Oncology shares in Q2 2017, an estimated $1.97M.
  • Sabby Management first reported a position in Coherus Oncology in Q2 2015 and held it in 3 quarters.
  • Sabby Management's Coherus Oncology position peaked at $1.97M in Q1 2017.
  • 106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.